H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)

July 9, 2026 6:53 AM

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $25.00 price target on CervoMed (NASDAQ: CRVO).The analyst commented: "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found